Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
INM
InMed Pharmaceuticals Inc
0.90
-0.0699 (-7.21%)
Volume: 11,447
Day Range: 0.90 - 0.9931
Last Trade Time: 7:37:35 PM EDT
WOLF TICKETS 2023
https://mailchi.mp/550c403a5512/inmed-provides-update-on-baymedica-rare-cannabinoid-business?e=5815d309bc
Likely to set all time highs now goin into this upcoming election year.. I got my shares from back in advanced tissue sciences days so I'm still in good shape.
Represent
DIAZ BLESS
$INM - Up 5% Pre-Market/ Current Price $1.14
Provides Update on BayMedica Rare Cannabinoid Business
$2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter
Third consecutive quarter with significant revenue growth
INM
InMed Pharmaceuticals Inc
0.935
-0.004699 (-0.50%)
Volume: 32,164
Day Range: 0.900201 - 1.07
Last Trade Time: 7:33:06 PM EDT
Another RS & shareholder wipeout incoming.
3 times in under 3 years.
INM
InMed Pharmaceuticals Inc
0.92
-0.10 (-9.80%)
Volume: 58,188
Day Range: 0.91 - 0.9997
Last Trade Time: 7:50:09 PM EDT
INM
InMed Pharmaceuticals Inc
0.92
-0.10 (-9.80%)
Volume: 58,188
Day Range: 0.91 - 0.9997
Last Trade Time: 7:50:09 PM EDT
INM
InMed Pharmaceuticals Inc
1.22
-0.06 (-4.69%)
Volume: 45,993
Day Range: 1.23 - 1.33
Last Trade Time: 7:53:52 PM EDT
INM
InMed Pharmaceuticals Inc
1.111
-0.109 (-8.93%)
Volume: 106,484
Day Range: 1.17 - 1.24
Last Trade Time: 7:56:25 PM EDT
INM
InMed Pharmaceuticals Inc
1.25
0.03 (2.46%)
Volume: 552,494
Day Range: 1.14 - 1.46
Last Trade Time: 7:40:44 PM EDT
INM
InMed Pharmaceuticals Inc
1.26
-0.19 (-13.10%)
Volume: 71,925
Day Range: 1.32 - 1.42
Last Trade Time: 7:51:49 PM EST
INM
InMed Pharmaceuticals Inc
2.14
0.06 (2.88%)
Volume: 477,684
Day Range: 1.85 - 2.24
Last Trade Time: 7:54:02 PM EST
ZALMY SAYS $3 INCOMING!!!! IM SLAPPING EVERYTHING AH BECAUSE I WANT THAT HUGE 50% GAIN!!!!! #ZALMYISKING
In at 164 dollars a share and down 10,000. Bought and bought and bought, and got bent over and over and over. Dead cat bounce.
You do you. I do me. Good luck
Bs...they'll piss through it mid 23'
Two (2) RS's & recapitalizations in under 3 years.
GL on a potential squeeze higher. def possible, but Adam's history speaks for itself.
Look at the 10 year chart.
$INM - They have enough cash to last through 2024. But who cares what happens in 11 months! Trade the trade today tomorrow and this week!
RS, recapitalization & more dilution slated for 2023.
Much to look forward to!
INM
$INM - Cost To Borrow is 420% ... make those shorts chase!!!!
$INM - undervalued in its current state!!!
This pos has been wiping out shareholders since 2016.
Look at 10 year chart.
Adam's is a shill.
Please do.
Get that shill of a ceo out of there too.
Adam's has been wiping the floor w/ his shareholders since 2016.
Another RS or delisting on deck.
Caution w/ this scam.
Look at the 10 year chart...lol
If they haven't Fck'd you yet, don't stick around to find out.
GLTA
Gw
$INM - lots of manipulation going on here. PPS is way undervalued. How can the stock drop from $3.50 to $1.60 in less than 2 days of trading.
COMPANY HAS MARKET CAP OF ONLY 2 MILLION $$$$$$$$$$$
LETS BUY WHOLE COMPANY
Should be priced near $10 PPS or how about $5.00
Company has $10M in cash. 1M OS
Classic pump n' dump on low floater. Increase volume to trigger volume scanners, More buying is stirred up, price doubles, triggers more price-increase scanners, more buying comes in, then next day DUMP YOUR LOAD on open into bagholders sacks.
Bagholders now, Twtr pump is over, maybe another round of front loaders get inducted soon, bwahhhh
Not unusual w/ inm.
F around long enough w/ this pos and find out. ;)
yes, INM
InMed Pharmaceuticals Inc
2.07
-0.14 (-6.33%)
Volume: 10,746,138
Day Range: 1.9601 - 3.03
Bid: 2.05
Ask: 2.10
Last Trade Time: 7:09:42 PM EST
Total Trades: 47,703
I can't believe we traded near 10M shares and we close red... WTF!
$INM - very cheap PPS. Going to milk it today!!!
,,,,,,,WE SHOULD BE AT $10 ALREADY—800K-FLOAT
,,,,,,,ACTIVATE BEAST MODE
,,,,,,,ACTIVATE BEAST MODE
$INM: And moving much higher today.... now 2.60
RUnnnnnnnnnnnnn foresttt........... Runnnnnnnnnnnnnnnnnnnnnn
GO $INM
Moving a little today $2
Moving today $2
INM
InMed Pharmaceuticals Inc
1.78
-0.08 (-4.30%)
Volume: 24,882
Day Range: 1.65 - 1.875
Last Trade Time: 4:00:01 PM EST
Great information
THANK YOU !
Whole moly, look at the share structure and cash value, analyst price target of $20 and Medical Cannabis. The only drawback it is Canadian outfit, which I hate, I have few thousand shares, and I am going to ride this one out, market cap ridiculously too low, 3 million market cap, give me a break. These are the reason why I bought, bottom play, market cap way too low, unjustifiably low, heavy short interest, massive short interest, Medical Cannabis Sector back in the day were the hottest stocks, back in 2015, some of these stocks ran for days, weeks and months. I will keep adding if the price stays below 3.50-3.75, once news is released with volume this will blow.
https://finance.yahoo.com/quote/INM/key-statistics?p=INM
Huge squeeze in play here, 800,000 float and only a market cap of 3 million dollars. Once news is released and volume comes in, this baby will fly instantly to 10 dollars, just needs news and volume the rest will be history.
INM
InMed Pharmaceuticals Inc
4.71
-0.11 (-2.28%)
Volume: 28,396
Day Range: 4.419 - 5.081
Bid: 3.53
Ask: 5.84
Last Trade Time: 4:46:39 PM EDT
Total Trades: 295
INM Detailed Quote
Followers
|
222
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9941
|
Created
|
05/21/14
|
Type
|
Free
|
Moderators |
A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.
InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
Investment Highlights
Bioinformatics: Proprietary Drug / Disease Targeting Tool
InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis.
Biosynthesis
Most of us are familiar with the two main bio-active ingredients produced by the cannabis (marijuana) plant, namely THC and CBD. In reality, however, there are 90+ cannabinoids in the plant that could have medical value but are too hard to research due to the fact that they only appear in trace amounts in each plant. InMed has developed, patented and intends to commercialize a process for producing all 90+ cannibinoids using genetically engineered bacteria to create bioidentical copies of these substances. Not only is their process less costly but it also produces these cannabinoids in large quantities at pharmaceutical grade purity. The following link provides a clear explanation of the process in laymen's terms.
Biosynthesis: The Science That May Unlock the Medical Potential of Cannabis
_________________________________________________________________________________________________________________________________________________________________________________
Pipeline
InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:
|
|
InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.
INM-750
Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. Through the development of INM-750, InMed is attempting to address this significant unmet medical need, for which there is no approved treatment or cure. INM-750 replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.
JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.
INM-085
INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.
Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.
Leadership
InMed's management team has well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.
Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.
He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.
Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.
Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years' of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Jeff Charpentier, CFO, Chief Financial Officer
Jeff Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.
InMed Pharmaceuticals, Inc. | NetworkNewsWire |
NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Corporate Presentation
https://www.inmedpharma.com/site/assets/files/1343/jan-cp-2017-2.pdf
InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.
Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.
INM-750 includes multiple cannabinoids as the active ingredients:
INM-085
Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.
INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.
INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.
Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources
Dermatology
Ocular
Pain and Inflammation
CNS
Respiratory
Metabolic Disease
The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the Cannabinoids
Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for unique pharmacological effects.
There are three general types of cannabinoids: herbal cannabinoids which occur uniquely in the cannabis, endogenous cannabinoids produced in the bodies of humans and animals and synthetic cannabinoids produced in the laboratory.
Cannabinoid Receptors
Before the 1980s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors. The discovery of the first cannabinoid receptors in the 1980s helped to clarify their role. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors, called CB1 and CB2.
CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions. Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.
CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.
The protein sequences of these two receptors are about 45% similar. In addition, minor variations in each receptor have been identified. There is some indication that other receptors exist, but none have been confirmed. Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid. Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage.
Herbal Cannabinoids
Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents. All herbal cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes. In addition to cannabinoids, the resin is rich in terpenes, which are largely responsible for the odor of the cannabis plant.
There are over ninety known herbal cannabinoids. Of these, tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent and have received the most attemtion. Other common cannabinoids include:
CBG | Cannabigerol |
CBC | Cannabichromene |
CBL | Cannabicyclol |
CBN | Cannabidiol |
CBV | Cannabivarol |
THCV | Tetrahydrocannabivarin |
CBDV | Cannabidivarin |
CBCV | Cannabichromevarin |
CBGV | Cannabigerovarin |
CBGM | Cannabigerol Monoethyl Ether |
THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective. THC has a greater affinity for the CB1 receptor than for the CB2 receptors. Its effects are perceived to be more cerebral.
CBD is not psychoactive, and appears to mediate the euphoric effect of THC. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea. CBD has a greater affinity for the CB2 receptor than for the CB1 receptor. It is perceived to have more effect on the torso than on the brain or CNS.
Cannabinoids were first discovered in the 1940s. The structure of THC was first determined in 1964. Due to molecular similarity and ease of synthetic conversion, it was originally believed that CBD was a natural precursor to THC. However, it is now known that CBD and THC are produced independently in the cannabis plant.
Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. The mixture of cannabinoids produced by a plant is known as the plant’s cannabinoid profile. Selective breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains of hemp, which are used as fiber, are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content, or for a specific chemical balance. Some strains of more than 20% THC have been created.
Cannabinoids can be administered by: smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat.
Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.
University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3
Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3
University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98
Hungary
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |